For the quarter ending 2026-03-31, VYGR made $2,593K in revenue. -$28,232K in net income. Net profit margin of -1088.78%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue | 2,593 | 15,336 | 13,365 | 5,200 |
| Research and development | 24,602 | 35,952 | 35,866 | 31,330 |
| General and administrative | 8,261 | 9,316 | 8,093 | 10,495 |
| Total operating expenses | 32,863 | 45,268 | 43,959 | 41,825 |
| Operating loss | -30,270 | -29,932 | -30,594 | -36,625 |
| Interest income | 1,912 | 2,111 | 2,385 | 2,831 |
| Other income | 435 | 404 | 400 | 427 |
| Total other income, net | 2,347 | 2,515 | 2,785 | 3,258 |
| Loss before income taxes | -27,923 | -27,417 | -27,809 | -33,367 |
| Income tax provision | 14 | 9 | 83 | 15 |
| Net loss | -27,937 | -27,426 | -27,892 | -33,382 |
| Net unrealized (loss) gain on available-for-sale securities | -295 | 25 | 228 | -22 |
| Total other comprehensive (loss) income | -295 | 25 | 228 | -22 |
| Comprehensive loss | -28,232 | -27,401 | -27,664 | -33,404 |
| Basic EPS | -0.47 | -0.465 | -0.47 | -0.57 |
| Diluted EPS | -0.47 | -0.465 | -0.47 | -0.57 |
| Basic Average Shares | 59,496,329 | 58,945,300 | 58,803,015 | 58,666,460 |
| Diluted Average Shares | 59,496,329 | 58,945,300 | 58,803,015 | 58,666,460 |
Voyager Therapeutics, Inc. (VYGR)
Voyager Therapeutics, Inc. (VYGR)